Indoco Remedies Ltd
NSE:INDOCO
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IN |
|
Indoco Remedies Ltd
NSE:INDOCO
|
19.8B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
995.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.2B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.7B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
231.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.3B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.7B USD |
Loading...
|
Market Distribution
| Min | -3 052.3% |
| 30th Percentile | 26.9% |
| Median | 39% |
| 70th Percentile | 53.3% |
| Max | 8 269.1% |
Other Profitability Ratios
Indoco Remedies Ltd
Glance View
Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-01-07. The firm is an integrated, research-oriented pharma company engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm's geographical segments include India and Outside India. The firm has nine domestic marketing divisions with a brand portfolio in various therapeutic segments, including Gastrointestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management and Gyneacology. The Company’s brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cal-Aid, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM and Methycal.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Indoco Remedies Ltd is 71%, which is above its 3-year median of 68.6%.
Over the last 3 years, Indoco Remedies Ltd’s Gross Margin has increased from 68.9% to 71%. During this period, it reached a low of 64.9% on Mar 31, 2024 and a high of 71% on Oct 30, 2025.
